Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keying Ma

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Expert Review of Clinical Immunology|February 18, 2026
Nipocalimab for the treatment of moderate-to-severe Sjögren's disease: a plain language summary of the DAHLIAS studyGhaith Noaiseh, Kathy L Sivils, Kim Campbell, et al.
Lancet (London, England)|November 24, 2025
Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trialGhaith Noaiseh, Kathy L Sivils, Kim Campbell, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 3, 2020
Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus ErythematosusMatteo Cesaroni, Loqmane Seridi, Matthew J Loza, et al.
RMD Open|June 28, 2024
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA studyPeter C Taylor, Georg Schett, Tom Wj Huizinga, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Expert Review of Clinical Immunology|February 18, 2026
Nipocalimab for the treatment of moderate-to-severe Sjögren's disease: a plain language summary of the DAHLIAS studyGhaith Noaiseh, Kathy L Sivils, Kim Campbell, et al.
Lancet (London, England)|November 24, 2025
Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trialGhaith Noaiseh, Kathy L Sivils, Kim Campbell, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 3, 2020
Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus ErythematosusMatteo Cesaroni, Loqmane Seridi, Matthew J Loza, et al.
RMD Open|June 28, 2024
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA studyPeter C Taylor, Georg Schett, Tom Wj Huizinga, et al.
Pageof 2